ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,701 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselNovaremed AG
Novaremed AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Novaremed AG develops non-opioid pharmaceutical therapies for the treatment of chronic neuropathic pain and peripheral neuropathies. Its lead candidate, nispomeben (NRD.E1), is an orally active small molecule in clinical development and is being evaluated in an NIH-supported Phase 2b trial for painful diabetic peripheral neuropathy with FDA Fast Track designation; an earlier-stage candidate, MP-101, targets prevention of chemotherapy-induced peripheral neuropathy.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Novaremed AG

✓ Offered4
Development of non-opioid pain therapies
Development of oral, non-opioid treatment options for chronic pain and neuropathic pain as an alternative to opioids.
Development of Nispomeben
Nispomeben (NRD.E1/NRD135S.E1), an orally available non-opioid small molecule, is being developed for the treatment of painful diabetic peripheral neuropathy.
Development of MP-101
MP-101, an orally active clinical candidate, is being developed to prevent chemotherapy-induced peripheral neuropathy.
Research and clinical development in peripheral neuropathy
Research and clinical development for peripheral neuropathy and neuropathic pain, including preclinical, Phase 1 and Phase 2 programmes.
Trust & reputation

ranQ Trust Score of Novaremed AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

Novaremed AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Novaremed AG scores 82.0 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.83.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
Novaremed AG scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
Novaremed AG scores 16.9 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.17.14%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.16.74%
Qualifications+0.00

Novaremed AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

May 9, 2025Media
Milestones achievements for life sciences startups
startupticker.ch

Knowledge

No knowledge articles yet

Once Novaremed AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Novaremed AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Novaremed AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Novaremed AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Thiersteinerallee 17
4053 Basel

At a glance

Legal form
Corporation
UID
CHE-416.510.898
Founded
2017 · 9 years
Last commercial register change
August 24, 2026
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    PA
    Prosalix AG
    Basel
    SC
    St. Clara Forschung AG
    Basel
    IM
    Inari Medical Europe GmbH
    Basel
    SB
    SOTIO Biotech AG
    Basel
    VT
    Vaderis Therapeutics AG
    Basel
    IF
    Institut für molekulare und klinische Ophthalmologie Basel
    Basel
    IS
    Immunovant Sciences GmbH
    Basel
    AH
    Alira Health AG
    Basel